Pembrolizumab - anti-PD-1 antibody

Preclinical

Pembrolizumab - anti-PD-1 antibody is one of 16 therapeutic programs targeting Solid Tumor, Adult. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Solid Tumor, AdultActive, not recruiting

Solid Tumor, AdultPreclinical

Active, not recruiting

Competition

Competitive Landscape

29 competitors in Solid Tumor, Adult

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 1

4 2

Avastin

Roche

Phase 1

2 3

Jakafi

Incyte

Phase 1

1 4

Tagrisso

AstraZeneca

Phase 1

1 5

Rybrevant

Johnson & Johnson

Phase 1

1 6

Imjudo

AstraZeneca

Phase 1

1 7

Imfinzi

AstraZeneca

Phase 1

1 8

Alimta

EEagle Pharmaceuticals, Inc.

Phase 1

1 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

1 10

Alimta

SShawn Eagle

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Solid Tumor, Adult1 trial

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab

Active, not recruiting·LLinnaeus Therapeutics, Inc.·Preclinical·NCT04130516·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pembrolizumab - anti-PD-1 antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Pembrolizumab - anti-PD-1 antibody. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Linnaeus Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: LLinnaeus Therapeutics, Inc.

Pembrolizumab - anti-PD-1 antibody

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Solid Tumor, Adult1 trial

References

Drug Info

Quick Facts

Related News